(0.59%) 5 158.11 points
(0.34%) 38 808 points
(0.58%) 16 249 points
(0.74%) $78.69
(2.52%) $2.20
(1.13%) $2 334.60
(3.24%) $27.56
(0.60%) $971.10
(-0.17%) $0.927
(-0.58%) $10.81
(-0.28%) $0.795
(-0.13%) $91.34
Live Chart Being Loaded With Signals
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform...
Stats | |
---|---|
今日成交量 | 756.00 |
平均成交量 | 0.00 |
市值 | 10 065.00 |
EPS | $-0.150 ( 2016-05-12 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2016-03-16 | Mitchell Daniel J | Sell | 8 862 | Common Stock |
2016-03-17 | Mitchell Daniel J | Sell | 12 468 | Common Stock |
2016-03-16 | Mitchell Daniel J | Sell | 112 | Common Stock |
2016-03-17 | Mitchell Daniel J | Sell | 158 | Common Stock |
2016-03-11 | Mitchell Daniel J | Sell | 76 662 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 99 transactions |
Buy: 1 518 952 | Sell: 29 605 418 |
音量 相关性
GlobeImmune, Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
GlobeImmune, Inc. 相关性 - 货币/商品
GlobeImmune, Inc. 财务报表
Annual | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $0 |
FY | 2015 |
营收: | $6.46M |
毛利润: | $6.46M (100.00 %) |
EPS: | $-0.480 |
FY | 2014 |
营收: | $5.97M |
毛利润: | $5.97M (100.00 %) |
EPS: | $-5.58 |
Financial Reports:
No articles found.
GlobeImmune, Inc.
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。